Thursday, October 17, 2013
An international team has found that neurokinin 1 substance P receptor, a known player in nausea, pain and inflammation,
signaling in breast cancer.1 The findings argue for combining
antagonists against both receptors to treat cancer.
Last year, Almendro's team
found that blocking substance
P, the principal ligand of TACR1,
reduced HER2+ breast cancer growth in vitro.5 In
the new study, the team showed that TACR1 is responsible for substance P's
effect on HER2 activity.
Mechanism to therapy
Almendro's finding is the most clear-cut
example to date for cross-activation of EGFR family members by GPCRs in cancer.
Nevertheless, mechanistic questions remain about precisely how TACR1 and other
GPCRs contribute to tumor growth.
Osherovich, L. SciBX 6(40); doi:10.1038/scibx.2013.1119 Published online
Oct. 17, 2013
1. Garcia-Recio, S. et
al. Cancer Res.; published online Sept. 12, 2013;
doi:10.1158/0008-5472.CAN-12-4573 Contact: Vanessa
Almendro, Hospital Clinic of Barcelona, Barcelona, Spain e-mail: firstname.lastname@example.org
P. et al. Oncogene 27, 4434-4445
S.-G. et al. Cancer Res. 71, 6535-6546 (2011)
A.J. et al. Nat. Rev. Cancer 10, 745-759 (2010)
C. et al. J. Cell Physiol. 227, 1358-1366 (2012)
6. George, A.J. et al.
J. Cell Sci.; published online Sept. 17, 2013; doi:10.1242/jcs.128280
COMPANIES AND INSTITUTIONS MENTIONED
Dana-Farber Cancer Institute, Boston, Mass.
Hospital Clinic of Barcelona, Barcelona, Spain
Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J.
The University of Queensland, Brisbane, Queensland, Australia